# Saci-IO TNBC (NCT04468061)

> Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC

No report yet. It can be ordered.

- Drugs tested: sacituzumab govitecan plus pembrolizumab; sacituzumab govitecan
- Indication: PD-L1-negative metastatic triple-negative breast cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04468061
- Phase: PHASE2
- Status: RECRUITING
- Sponsor: Dana-Farber Cancer Institute
- Conditions: Breast Cancer; Triple Negative Breast Cancer; PD-L1 Negative
- Interventions: Sacituzumab Govitecan; Pembrolizumab
- Enrollment: 110
- Primary outcome: Progression Free Survival (PFS)

## Indexed commentary on Saci-IO TNBC so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 5
- YouTube: 3
- Podcasts: 2

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=saci-io-tnbc-nct04468061

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04468061", "email": "<work email>"}; the inbox owner confirms by the emailed link.